期刊文献+

紫杉醇微孔载药支架在非ST段抬高急性冠脉综合征介入治疗中的应用研究 被引量:2

Study on application of Yinyi TM paclitaxel-eluting stent in the treatment for non ST elevation acute coronary syndrome
下载PDF
导出
摘要 目的评价垠艺TM紫杉醇微孔载药支架在非ST段抬高急性冠脉综合征介入治疗中的安全性和有效性。方法将97例非ST段抬高急性冠脉综合征患者随机分为实验组47例和对照组50例,分别置入垠艺TM紫杉醇药物涂层支架60枚和Partner支架72枚。随访术后6个月2组不良心脏事件(MACE)发生率,术后30 d MACE及术后6个月再狭窄率。结果 2组随访6个月,均无心源性死亡、非致死性心肌梗死。实验组8例、对照组3例冠脉造影复查时发现支架内再狭窄,予行支架内球囊扩张术治疗,手术成功。结论置入垠艺TM紫杉醇药物涂层支架术后6个月,冠脉再狭窄率和MACE发生率与置入Partner者相似,这一结论仍有待大规模、多中心的随机对照试验进一步证实。 Objective It is to evaluate the safety and efficacy of Yin YiTM paclitaxel-eluting stent in the interventional therapy for non ST elevation acute coronary syndrome.Methods 97 patients with non ST elevation acute coronary syndrome were randomly divided into two groups: 47 cases in experimental group and 50 cases in control group,and they were implanted 60 Yin YiTM paclitaxel-eluting stents and 72 Partner stents respectively.MACE after 6 months and after 30 days,ISR after 6 months were in both groups followed up after operation.Results There was no cardiogenic death case and non-fetal myocardial infarction case during six months' following up in both group.8 cases with stent restenosis in experimental group and 3 cases in control group were found by coronary arteriongraphy,and they were treated with stent balloon dilatation.All the operations were successful.Conclusion In 6 months after Yin YiTM paclitaxel-eluting stent implanting,coronary artery restenosis rate and MACE occurrence rate is similar to Partner stent.This conclusion still need to be further confirmed by large-scale,multi-center,randomized controlled trials.
作者 谢勉 党群
出处 《现代中西医结合杂志》 CAS 2011年第13期1566-1568,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 垠艺TM紫杉醇微孔载药支架 经皮冠状动脉介入治疗 Partner雷帕霉素支架 Yin YiTM paclitaxel-eluting stent percutaneous coronary intervention Partner sirolimus-eluting stent
  • 相关文献

参考文献17

  • 1Degertekin M, Regar E,Tnaabe K,et al. Sirolimus-eluting Stent for treatment of complex in-stent restenosis: the first clinical experience [ J]. J Am Coil Cardio,2003,41:184 - 189.
  • 2Moses JW, Leon MB, Popma JJ. Sirolimus-eluting stents versus standard stent In patients with stenosis in a native coronary artery [J]. N Engl J Med,2003,49:1315-1323.
  • 3Silber S,Albertsson P,Aviles FF, et al. Guideline for Pereutnaeous coronary interventions:the task force for Pereutaneous coronary interventions of the Europeans society of cardiology[J]. Eur Heart J, 2005,26 ( 8 ) : 804 - 847.
  • 4Horwitz SB. How to make taxol from scratch[ J]. Nature,1994,367 (17) :593 -598.
  • 5柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2146
  • 6Donald E, Cutlip,Stephan Windecker, et al. On behalf of the Academic Research Consortium. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions [ J ]. Circulation, 2007, 115:2344 -2351.
  • 7Grube E,Silber S, Hauptman KE,et al. First five-year clinical fol- low-up from a randomized trial of a polymer-based, paclitaxel-eluting stent:TAXUS- l [J]. J Am CollCardio,2006,9S(SA):141M.
  • 8Serruys PW, Degertekin M,Tanbae K, et al. TAXUS- Ⅱ Study Group. Vascular responses at proximal and distal edges of paclitax- el-eluting stems: serial intravascular ultrasound analysis from the TAXUS - Ⅱ trial[ J ]. Circulation ,2004,109:627 - 633.
  • 9Tanabe K,Serruys PW, Grube E, et al. TAXUS- Ⅲ Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation [ J ]. Circulation, 2003,107 (4) :559 -564.
  • 10Grube E,Silber S, HauPtmnan KE, et al. Six-and twelve-month resuits from a randomized,double-blind trial on a slow-release Paelitaxel-eluting stent for de novo coronary lesions [ J]. Cireulation, 2003,107:38 - 42.

二级参考文献38

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Albiero R,Nishida T,Adamian M,et al.Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents.Circulation,2000,101:2454-2457.
  • 3Costa MA,Sabat M,van der Giessen WJ,et al.Late coronary occlusion after intracoronary brachytherapy.Circulation,1999,100:789-792.
  • 4Suzuki T,Kopia G,Hayashi S,et al.Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.Circulation,2001,104:1188-1193.
  • 5Sousa JE,Costa MA,Abizaid A,et al.Lack of noeintimal proliferation after implantation of sirolimus-coated stents in human coronary arteries.Circulation,2001,103 :192-195.
  • 6Tamai H,Igaki K,Kyo E,et al.Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.Circulation,2000,102:399-404.
  • 7Buergler JM,Tio FO,Schulz DG,et al.Use of Nitro-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs.Coron Artery Dis,2000,11: 351 -357.
  • 8Mohacsi PJ,Tuller D,Hulliger B,et al.Different inhibitory effect of immunosupressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell groth factor.J Heart Loung
  • 9Gallo R,Padurean A ,Jayaraman T,et al.Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.Circulation,1999,99:2164-2170.
  • 10Lincoff AM,Furst JG,Ellis SG,et al.Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.J Am Coll Cardiol,1997,29: 808-816

共引文献2156

同被引文献39

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部